Gubra links with pharma major to develop next generation obesity treatments

Danish privately-held biotech firm Gubra has entered into a collaboration and license agreement for the development of novel peptide compounds to treat obesity with German family-owned pharma major Boehringer Ingelheim.

The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. It further expands and complements Boehringer Ingelheim’s comprehensive research and development portfolio in cardiometabolic diseases, one of the company’s core focus areas.

Under the terms of the agreement, Gubra may receive up to 250 million euros ($300 million) in upfront and success-based development and commercialization milestone plus staggered up to double-digit royalties on worldwide net sales.